Hot off the press from Shane Storey at Wilsons, one of OZ Life...

Hot off the press from Shane Storey at Wilsons, one of OZ Life Science's most respected analysts...(has unrisked valuation of $2.20 in report, obviously over years). He has picked one like this before!!!

First patient enrolled in the OncoPac-1 trial

We maintain our BUY rating with a revised price target of 38cps ($2.00 un-risked on a three-year view). Oncosil Medical has enrolled the first subject in its OncoPac-1 clinical trial. This clinical trial seeks to establish OncoSilTM as a first-line therapy for patients diagnosed with locally advanced pancreatic cancer (LAPC). LAPC is a swiftly lethal disease in which conventional radiotherapy struggles for significance, taking too long to administer and adding too much toxicity over chemotherapy. OncoSilTM is an old idea in some ways but the chance of being able to deliver a tumour-killing dose of radiation in one procedure with good safety has seen major oncology centres join the queue to get their LAPC patients into OncoPac-1. Once the trial’s “pilot” phase is over and it launches nationally in the USA, we think the stock will capture some much deserved investor attention.